News Sentiment

IXHL sentiment intelligence

Incannex Healthcare Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 71 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 3.39 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 71

directly relevant articles

Source quality 7

high-authority source matches

Trend context Trend inactive

-14.6% over one week, -11.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -14.6% Price reacting lower
Trend fit Trend inactive -11.5% over four weeks
Fair value -92.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 44
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 71
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
GlobeNewswire 6
Investing.com 5
Meyka 4
StockStory 3
Market source 3
MarketBeat 3
Barron's 3

Event Lens

What the news is about

Classified themes
Market update 49
Earnings 11
Balance sheet 4
Capital return 3
Analyst action 3
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 71
Stock Titan Direct company coverage

Incannex (NASDAQ: IXHL) earns MedTech Breakthrough award for IHL-42X sleep apnea therapy

Incannex Healthcare Inc. (NASDAQ: IXHL) has been awarded the “Best New Technology Solution for Drug Development” in the 10th annual MedTech Breakthrough Awards for its lead drug candidate, IHL-42X. This oral fixed-dose combination therapy is being developed for obstructive sleep

Tone
Positive 75/100
Event
Market update
Published
10 May 2026 21:40
Source
Stock Titan
MarketBeat Direct company coverage

Incannex Healthcare (NASDAQ:IXHL) Stock Price Up 2.8% - Here's Why

Incannex Healthcare (NASDAQ:IXHL) saw its share price rise 2.8% during mid-day trading to $4.75, with approximately 254,209 shares changing hands. Despite the increase, the stock carries a consensus "Sell" rating from analysts, including recent downgrades from Weiss Ratings and W

Tone
Negative 39/100
Event
Analyst action
Published
10 May 2026 21:40
Source
MarketBeat
MarketBeat Direct company coverage

Incannex Healthcare (IXHL) Expected to Announce Earnings on Thursday

Incannex Healthcare (IXHL) is slated to announce its Q3 2026 earnings on Thursday, May 14th, with analysts anticipating an EPS of ($0.60) and $0.20 million in revenue. The company, a clinical-stage biopharmaceutical firm focusing on cannabinoid and psychedelic therapies, is curre

Tone
Negative 40/100
Event
Earnings
Published
08 May 2026 18:08
Source
MarketBeat
Stock Titan Direct company coverage

IXHL SEC Filings - Incannex Healthcare Ltd 10-K, 10-Q, 8-K Forms

This page provides a comprehensive record of Incannex Healthcare (IXHL) SEC filings, including annual, quarterly, and current reports, as well as insider trading forms. Each filing is accompanied by an AI-generated summary, sentiment and impact scores, and end-of-day stock perfor

Tone
Neutral 50/100
Event
Market update
Published
06 May 2026 04:09
Source
Stock Titan
Stock Titan Direct company coverage

Incannex (NASDAQ: IXHL) links PSX-001 anxiety program to new U.S. psychedelic order

Incannex Healthcare Inc. (NASDAQ: IXHL) announced that its PSX-001 oral synthetic psilocybin program for Generalized Anxiety Disorder aligns with a new White House Executive Order aimed at accelerating access to psychedelic treatments for serious mental illness. The company repor

Tone
Positive 71/100
Event
Market update
Published
25 Apr 2026 12:38
Source
Stock Titan
Stock Titan Direct company coverage

Incannex Healthcare (NASDAQ: IXHL) restarts share buyback, holding $75M cash and no debt

Incannex Healthcare (NASDAQ: IXHL) has reactivated its share repurchase program, having already bought back shares, citing a belief that its current market valuation does not accurately reflect its financial strength and clinical progress. The company boasts approximately $75 mil

Tone
Positive 73/100
Event
Capital return
Published
13 Apr 2026 04:40
Source
Stock Titan
Stock Titan Direct company coverage

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

Incannex Healthcare (NASDAQ: IXHL) has partnered with the AASM Foundation to sponsor a 2026 Focused Projects Grant for junior investigators in sleep apnea research, coinciding with Incannex's advancement of its lead investigational oral fixed-dose combination, IHL-42X. The compan

Tone
Positive 74/100
Event
Regulatory and legal
Published
24 Mar 2026 09:09
Source
Stock Titan
MarketBeat Direct company coverage

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update

Incannex Healthcare Inc. (NASDAQ:IXHL) experienced a significant 96.1% drop in short interest during February, bringing the total to 842,808 shares, which represents about 7.2% of its shares short. Despite analysts maintaining a "Sell" rating overall, institutional ownership rema

Tone
Neutral 50/100
Event
Analyst action
Published
13 Mar 2026 12:39
Source
MarketBeat
The Globe and Mail Direct company coverage

Incannex Healthcare Announces $10 Million Direct Offering

Incannex Healthcare Limited (IXHL) announced a $10 million registered direct offering of common stock and warrants to healthcare-focused institutional investors, expected to close around March 13, 2026. The new capital, combined with existing funds, is intended to finance the com

Tone
Neutral 50/100
Event
Market update
Published
13 Mar 2026 07:46
Source
The Globe and Mail
Stock Titan Direct company coverage

Incannex $10M raise funds DReAMzz Phase 2 trial, preserves Phase 3 cash

Incannex Healthcare (Nasdaq: IXHL) has priced a registered direct offering to raise $10 million by issuing 2,000,000 common shares and accompanying warrants. The proceeds are intended to fund the completion of the DReAMzz Phase 2 study for IHL-42X, while existing cash will be pre

Tone
Negative 37/100
Event
Balance sheet
Published
13 Mar 2026 03:51
Source
Stock Titan
Meyka Direct company coverage

IHL.AX Incannex Healthcare (ASX) A$0.041 -10.87% intraday 10 Mar 2026: watch volume

Incannex Healthcare Limited (IHL.AX) experienced significant intraday volatility on March 10, 2026, with its stock price dropping 10.87% to A$0.041 on extremely high trading volume. This movement is attributed to its thin capitalization, recent clinical updates, low liquidity, an

Tone
Negative 29/100
Event
Balance sheet
Published
10 Mar 2026 03:51
Source
Meyka
Meyka Direct company coverage

IHL.AX Incannex Healthcare (ASX) A$0.041 -10.87% intraday Mar 2026: high volume

Incannex Healthcare (IHL.AX) experienced a significant intraday drop of 10.87% to A$0.041 on March 3, 2026, with unusually high trading volume, making it one of ASX's most active stocks. The article highlights the company's financial metrics, clinical pipeline in cannabinoid and

Tone
Neutral 50/100
Event
Market update
Published
03 Mar 2026 23:51
Source
Meyka
The Globe and Mail Direct company coverage

Incannex Healthcare Announces 1-for-30 Reverse Stock Split

Incannex Healthcare Limited (IXHL) announced a 1-for-30 reverse stock split of its common stock, effective February 26, 2026, to boost its per-share trading price and regain compliance with Nasdaq's minimum bid price requirement. The split will reduce the share count from approxi

Tone
Negative 40/100
Event
Market update
Published
27 Feb 2026 07:09
Source
The Globe and Mail
Quiver Quantitative Direct company coverage

Incannex Healthcare Inc. Announces 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance | IXHL Stock News

Incannex Healthcare Inc. announced a 1-for-30 reverse stock split, effective February 26, 2026, to meet Nasdaq's minimum bid price requirement. This action will reduce the outstanding shares from approximately 358 million to 11.9 million, aiming to increase the stock's per-share

Tone
Negative 38/100
Event
Market update
Published
25 Feb 2026 14:30
Source
Quiver Quantitative
Meyka Direct company coverage

IHL.AX stock falls to A$0.041 on heavy volume: what traders should watch next

Incannex Healthcare Limited (IHL.AX) stock closed at A$0.041, down 10.87%, with trading volume ten times the 30-day average. The heavy selling pressure and high volatility are attributed to renewed market attention and the company's binary clinical risks in cannabinoids and psych

Tone
Negative 28/100
Event
Market update
Published
22 Feb 2026 00:53
Source
Meyka
Meyka Direct company coverage

IHL.AX Incannex Healthcare ASX pre-market 20 Feb 2026: 61.36M shares active

Incannex Healthcare (IHL.AX) saw significant pre-market activity on February 20, 2026, with over 61.36 million shares traded, leading to a 10.87% drop in price to A$0.041. This high volume indicates elevated investor attention, primarily driven by the company's clinical pipeline

Tone
Neutral 50/100
Event
Market update
Published
18 Feb 2026 23:52
Source
Meyka